Novel peptide-based HIV-1 immunotherapy (Q35684864)

9 August 2017

1 reference

title

Novel peptide-based HIV-1 immunotherapy (English)

1 reference

9 August 2017

1 reference

Maja A Sommerfelt

1

1 reference

9 August 2017

Jørgen Nyhus

series ordinal

2

1 reference

9 August 2017

Birger Sørensen

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Biological Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

349-361

1 reference

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Skewed maturation of memory HIV-specific CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Structured treatment interruptions in antiretroviral management of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Structured treatment interruptions in HIV/AIDS therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

HIV-1 sequence variation: drift, shift, and attenuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

HIV-1 Nef impairs MHC class II antigen presentation and surface expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

HIV preferentially infects HIV-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Ongoing trials of immune-based therapies for HIV infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Strategies for designing and optimizing new generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Human T-cells recognise N-terminally Fmoc-modified peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

AIDSVAX results: an important open question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Cross-presentation in viral immunity and self-tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Immune tolerance after delivery of dying cells to dendritic cells in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Exploiting dendritic cells to improve vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.349

21 January 2018

Identifiers

DOI

10.1517/14712598.4.3.349

1 reference

9 August 2017

1 reference